Senior prescription drug costs could hit $1.8 trillion over next 10 years,meaning benefit covering half would entail spending some $900 billion
The Weekly Roundup: September 23-27
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
LEO Pharma Presents Extensive Data at EADV
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations
Post Hoc Analysis of Vilobelimab in Hidradenitis Suppurativa Suggests Clinically Meaningful Benefits